Medical Excellence Capital, a Nissequogue, NY-based early-stage life science venture firm formed to invest in disruptive technologies in precision health, held a $145m final close of Medical Excellence Capital Partners, LP.
MEC was formed to leverage the combination of a proven investment team and a unique network of physician-scientists to focus on company creation and venture investing. Target investment areas include cell therapy, gene therapy, AI/ML applied to drug discovery, synthetic biology, and regenerative medicine.
Founded by John Prufeta, founder and general partner, Medical Excellence Capital provides company creation, seed, and early-stage capital to innovators in the areas of cell therapy, gene therapy, AI/ML applied to drug discovery, immunology/drug resistance, and regenerative medicine. MEC invests solely in high potential companies where its expertise, insights, and global network can promote acceleration and maximized value creation. It is closely aligned and networked with Medical Excellence Group (MedEx), an extensive global, private health advisory medical network and family office health care platform, built and refined over the last 15 years by Mr. Prufeta. This platform includes a network of more than 1,200 top physician and scientist leaders across 33 major academic medical centers and research institutions in the US. The Medical Excellence Capital team operates out of the significant health care innovation markets New York, California, and Pennsylvania.
The team includes Brian Halak, Ph.D., Eric Heil, MBA, and Kim Kamdar, Ph.D., while the MEC Scientific Advisory Board is comprised of:
- Euan Ashley, M.D., Ph.D., Stanford Medical School – Associate Dean and Professor of Genetics and Precision Health Cardiovascular, and Data Science
- Gregg Semenza, M.D., Ph.D., Johns Hopkins Medicine – 2019 Nobel Prize Laureate in Medicine; Professor of Genetic Medicine
- Steven Tsang, M.D., Ph.D., Columbia Medicine – Professor of Ophthalmology, and Pathology and Cell Biology; Director of the Columbia Stem Cell Institute
- Douglas Wallace, Ph.D., Children’s Hospital of Philadelphia (CHOP) & University of Pennsylvania – Director of the Center for Mitochondrial and Epigenomic Medicine
The portfolio includes:
- Aspen Neuroscience
- Immunitas Therapeutics
- Nobias Therapeutics
- Pleno
- ProJenX
- Rejuvitas
- SonoThera
FinSMEs
23/08/2022